Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor relapsed following treatment with curative intent for early disease, which must have included immunotherapy and chemotherapy as part of the radical locoregional therapy (either adjuvant, neoadjuvant or both).

Trial Details

NCT ID

NCT05582538

Phase

PHASE2

Sponsor

IFOM ETS - The AIRC Institute of Molecular Oncology

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Ceralasertib
Durvalumab
Nab-paclitaxel

Locations (sample)

Novara, Novara, Italy|45.44694,8.62118
Bergamo, Italy|45.69601,9.66721
Milan, Italy|42.78235,12.59836
Naples, Italy|40.85216,14.26811
Padova, Italy|44.38225,11.14261

Key Eligibility Criteria

ATRiBRAVE trial written informed consent, prior to any study specific procedures
Age ≥18 years old
Ability to comply with the study protocol in the investigator's judgment.
Ability to swallow and retain oral medication

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →